According to Lieutenant Colonel, Associate Professor, Assoc. Prof. Dr. Chu Van Men, Director of the Center for Clinical Trials and Bioequivalence, Military Medical Academy, phase 3 injected the Nano Covax vaccine to 13,000 people and administered only a single dose group injection. at least 25 mcg and the placebo injection group. Specifically, according to the protocol approved by the Ministry of Health, the first 1,000 trial injectors of the first phase of phase 3, the volunteers are injected with the ratio of “6 people vaccinated, 1 person injected placebo”. The remaining 12,000 people injected according to the ratio “2 people vaccinated, 1 person injected placebo”. It is expected that the first phase of phase 3 will be conducted by the Military Medical Academy and the Pasteur Institute in Ho Chi Minh City with 1,000 volunteers, each with 500 people. Vietnam’s first COVID-19 vaccine tested in phase 3 on humans. Regarding the reason for choosing the dose group of 25 mcg, Assoc. Prof. Dr. Chu Van Men said that testing at 3 dose levels of 25-50-75 mcg showed that the vaccine was safe on volunteers, capable of generating immunity in 3 doses. There was no difference in dose groups. Therefore, the National Ethical Council in Biomedical Research, Ministry of Health decided to only inject 1 optimal dose of 25 mcg at this stage. Phase 3 is implemented in many centers in the country: The North is deployed by the Military Medical Academy as the focal point at Military Medical Hospital 103, in collaboration with the Preventive Medicine Center of Hung Yen province to deploy locally; In the South, the Ho Chi Minh City Pasteur Institute is the focal point to deploy, in collaboration with the Preventive Medicine Centers of Long An and Tien Giang provinces to deploy locally. After the phase 1 and phase 2 trials, the Nano Covax vaccine is judged to be quite safe, so the criteria for recruiting volunteers will be relaxed more than the previous two phases. 13,000 volunteers participating in phase 3, aged 18-75 years old, only need to check their blood count and check for antibodies to the SARS-CoV-2 virus. People who have been exposed to the SARS-CoV-2 virus or already have antibodies will be excluded from the test population. As of June 11, more than 6,500 volunteers have registered to test the Nano Covax vaccine against COVID-19 phase 3. Senior Colonel, Assoc. Prof. Dr. Ho Anh Son, Deputy Director of the Military Medical and Pharmaceutical Research Institute, Military Medical Academy added: “It is expected that by mid-September 2021, after about 42 days of the second injection. In two of the first 1,000 experimental injections, we will summarize the results of the quality assessment to report. If it is favorable, we will submit the dossier and propose the Government, the Ministry of Health, and the National Ethical Council in the study. In parallel with that process, the unit will continue to test the Nano Covax vaccine on 12,000 volunteers to continue to control the experimental injection and evaluate the effectiveness. protective power of vaccines”. During the testing process and after the antibody sample is available, the Military Medical Academy will coordinate with the Nanogen Pharmaceutical Biotechnology Joint Stock Company, the testing units to conduct the assessment of the ability to neutralize the SARS-CoV virus. -2 in the laboratory for existing virus strains to determine the development direction of vaccine research in the coming period. Through discussions with the expert group of Nanogen Pharmaceutical Biotechnology Joint Stock Company, in addition to recombinant protein technology, there are other technologies for research and production of vaccines. Nanogen as well as many Vietnamese scientists are very interested in mRNA technology – which has been of great interest to the world in recent years. This technology has the advantage of reacting very quickly to the disease, quickly getting a vaccine. According to available information, vaccines produced by this technology are very safe for human use. More information about the phase 3 trial, Lieutenant General, Prof. Dr. Do Quyet, Director of the Military Medical Academy, said that this trial phase is designed according to the adaptive design method, continuing to inject the experimental vaccine. trial and placebo group; health assessment at the time of the first injection, the second dose (done on the 28th day), the 35th day and the 42nd day after injection. The Director of the Military Medical Academy expressed confidence in the safety of the Nano Covax vaccine with the results achieved through the previous two testing phases. Specifically, the concentration of SARS-CoV-2 virus antibodies after the phase 2 trial injection showed that the antibody titre increased very high, from tens to hundreds of times. After the second injection, the volunteers had a physical examination (blood test, blood pressure measurement…) once a week to assess the amount of antibodies appearing in the body; then continue to be monitored for 6 months to get information, assess health as well as immunity ability. Up to now, 100% of volunteers who have been vaccinated with Nano Covax vaccine have produced antibodies in the blood. – Phase I (December 2020), the COVID-19 vaccine Nano Covax was administered to 60 volunteers. – Phase II (February 2021) injected over 554 people. From phase 2, the trial was conducted both at the Military Medical Academy and the Medical Center of Ben Luc district – Long An province (by the Pasteur Institute in Ho Chi Minh City).

Illustration. At the meeting of the National Steering Committee for COVID-19 prevention and control on the afternoon of June 11, Deputy Minister of Health Tran Van Thuan informed that the Ministry of Health had officially approved the phase 3 clinical trial of the vaccine. Vietnam’s first COVID-19 room named Nano Covax. According to Deputy Minister Tran Van Thuan, the Ministry of Health has just approved the phase 3 clinical trial of Nano Covax vaccine of Nanogen Company. According to Lieutenant Colonel, Assoc. Dr. Chu Van Men – Director of the Center for Clinical Trials and Bioequivalence, Military Medical Academy, Ministry of National Defense, phase 3 injected the Nano Covax vaccine to 13,000 people and injected only a single dose group. 25 mcg and placebo injection group (with a ratio of “6 people vaccinated to 1 person injecting placebo” according to the design approved by the Ministry of Health). As for the reason for choosing the 25 mcg dose group, Assoc. Prof. Dr. Chu Van Men said that when the phase 2 trial showed that, the 3 dose levels of 25-50-75 mcg had equivalent safety and immunogenicity. undifferentiated. Therefore, in order to ensure the safety and increase the effectiveness of the number of doses of vaccine production, the National Ethical Council in Biomedical Research, the Ministry of Health decided to inject only 1 optimal dose of 25 mcg at the initial stage. this. Minister of Health Nguyen Thanh Long and Minister of National Defense Phan Van Giang asked and encouraged volunteers to test the vaccine against COVID-19 Nano Covax. Photo: PV. On June 11, the Military Medical Academy said that this unit has started to deploy the phase 3 trial injection of the COVID-19 Nano Covax vaccine for the first 19 volunteers. On the day of injection for 200 people, divided into 2 groups. Accordingly, one group injected the Nano Covax vaccine with a dose of 25mcg, the other group injected a placebo with aluminum excipients. Military medical students will inject 1,000 volunteers in the first time. According to the research outline, phase 3 will test on about 13,000 volunteers in many provinces such as Hanoi, Hung Yen, Long An, Tien Giang… At the Military Medical Academy, there are currently more than 7,000 volunteers registered to participate in the trial, of which more than 600 people have been screened and are eligible to participate. Besides, IVAC’s Covivac vaccine is also preparing to complete phase 1 trial and enter phase 2 in July 2021. Regarding the subjects of vaccination, according to Deputy Minister Tran Van Thuan, in addition to the priority subjects for COVID-19 vaccination under Resolution 21, the Ministry of Health has added workers in industrial zones and will propose more subjects working in establishments dealing in essential goods.

National Assembly Chairman Vuong Dinh Hue visits the vaccine research and production laboratory of the Military Medical Academy – Photo: Thanh Chung A representative of the Military Medical Academy said that it has successfully researched and manufactured a test kit to detect the new strain of corona virus (SARS-CoV-2) by real-time RT-PCR method, used at more than 100 facilities. healthcare throughout the country and exported to 18 countries around the world. Continuing to research and successfully manufacture Amphabio PCR test kits with the ability to test quickly and in large quantities at the same time, which is currently being used effectively in Bac Giang province. Notably, the Academy has been trusted by the Ministry of Health to carry out phase 1 and 2 clinical trials for the Nano Covax vaccine against Covid-19 (from December 2020) and both are generating antibodies. It is expected that from June 2021, there will be a phase 3 clinical trial, deploying over 13,000 volunteers 18 years of age or older. In addition, the Academy has mobilized staff to support the prevention and control of Covid-19 in Quang Nam, Bac Giang, Bac Ninh and Laos. National Assembly Chairman Vuong Dinh Hue visited and worked at the Military Medical Academy – Photo: Thanh Chung Speaking at the meeting, National Assembly Chairman Vuong Dinh Hue highly appreciated the efforts and achievements that the Military Medical Academy has achieved during 72 years of construction and growth, which has received the most noble achievements of the Party. , state and military. In particular, in the prevention and control of the Covid-19 epidemic, the Military Medical Academy is one of the active, active and effective participating units. National Assembly Chairman Vuong Dinh Hue said that in the current period, the task of effective disease prevention is the focus in the implementation of “dual duty”, so vaccines are an important “weapon”, strategic, decisive issues to end and conquer disease. “The XIII Congress of the Party has set a key task of focusing on controlling the Covid-19 pandemic, mass vaccination of the community with Covid-19 vaccine. Therefore, the Military Medical Academy closely coordinates with other agencies. Relevant ministries and sectors urgently speed up the phase 3 clinical trial of the Nano Covax vaccine against Covid-19, striving for early results to have a preventive vaccine for the community” – National Assembly Chairman assigned. The National Assembly Chairman also suggested that the Military Medical Academy should identify challenges such as, there are many domestic and foreign facilities focusing on research and production of vaccines. Mr. Vuong Dinh Hue analyzed that if there is no superior vaccine in terms of quality, price and supply quantity, it will fall into an opportunity trap. A number of vaccine products have been born and put into circulation in countries, along with rigorous testing by the health systems of countries, approved by WHO. However, there is currently a vaccine that has shown its effectiveness compared to the new variant; There are scenarios of monopolistic production, imposing price and quantity, but also opportunities for technology transfer in the direction of humane sharing. “So, the Military Medical Academy to research and produce vaccines, it is necessary to have the shortest time of antibodies, the shortest number of days, the better. The side effects must be minimized, especially for people with underlying diseases. and weak health. Having the ability to resist and adapt to new variants of the virus,” suggested the National Assembly Chairman. At the meeting, the Military Medical Academy proposed to allow the Academy to organize the implementation of the project “Research and Development Center for Human Infectious Diseases” which was approved by the Prime Minister at the government office. Document No. 164 dated December 31, 2020 of the Government Office, which is expected to have a number of functions and tasks such as research on pathogens, development and production of biological products for detection, diagnosis and treatment of diseases. treating infectious diseases, especially dangerous and extremely dangerous diseases, contributing to protecting the health of soldiers and people, especially in emergency and disaster situations. Researching foundational technologies in development, technology transfer and production of vaccines against infectious diseases, especially dangerous and dangerous infectious diseases. Agreeing with the proposal of the Military Medical Academy, National Assembly Chairwoman Vuong Dinh Hue suggested, the Academy needs a state-level scientific research program and emergency approval to research and test. production of vaccines for human infectious diseases. The Ministry of National Defense shall assume the prime responsibility for, and coordinate with relevant agencies in, facilitating and directing the Military Medical Academy to accelerate the implementation of the project “Research and development center for human infectious diseases vaccines” under the theme of: Government policy. Also this afternoon, National Assembly Chairman Vuong Dinh Hue visited the vaccine research and production laboratory at the Military Medicine Research Center building, under the Military Medical Academy. The National Assembly Chairman graciously encouraged the forces directly involved in research, production and volunteers to test the Covid-19 vaccine.

In this phase 3, Nano Covax vaccine will be tested in multi-centers at domestic facilities with the deployment of vaccination for 13,000 volunteers. Specifically, in the North, experimental injections were carried out at the Military Medical Academy (Hanoi) and in Hung Yen province; The southern area is carried out by the Pasteur Institute in Ho Chi Minh City, and is planned to be injected in 2 provinces: Long An and Tien Giang. In the immediate future, in phase 3, 1,000 registered volunteers will be tested, and then continue to recruit more. In this phase 3, there is also research and evaluation of the effect of the vaccine against the variant of the SARS-CoV-2 virus found for the first time in India. By the end of September 2021, after the phase 3 trial is completed, depending on the test results and epidemic developments, the vaccine will be considered for approval for emergency use on a large scale in our country. Step 1: Visit https://www.bluezone.gov.vn or download directly at App Store or CH Play. Step 2: Once downloaded, the application will ask for permission to use Bluetooth to record contact with other Bluezone installed users. If Bluetooth is not open, drag the status bar and turn on Bluetooth; or go to Settings, select Bluetooth and turn it on. Step 3: Once the installation is done, click Scan Around. If someone near you less than 2m has used Bluezone, the application will automatically identify these users and put them in the contact list.

Illustration GS. Dr. Truong Viet Dung, Chairman of the National Ethics Council in Biomedical Research, said in the SK & DS newspaper, in phase 3, the subjects of the Nano Covax vaccine trial in Vietnam will expand. The object here means the area, which can be extended to other areas such as workers in industrial zones. However, areas or industrial zones with COVID-19 cases were not selected for clinical trials because it would be interpreted as the epidemic situation that made people too worried and accepted to participate in the research. Therefore, research can only be carried out in industrial zones at risk of disease outbreaks, not in industrial zones with epidemics. Testing participants for COVID-19 to confirm the absence of antibodies is required. In the spirit of “testing as quickly as possible” of the Government, the Ministry of Health assigned testing units. Fast does not mean cutting, skipping stages. Any stage must comply with international requirements and standards. Do it very quickly but must be very standard, giving it to the Council must be approved immediately. In general, in accordance with the process and step by step of each phase, so that the Ministry of Health has enough scientific basis to be able to grant urgent and conditional use of Nano Covax vaccine in Vietnam. Information on Vietnam plus, Deputy Director of Military Medical Research Institute Ho Anh Son said that according to the latest information, it is possible that as soon as next week (expected in early June 2021) will enter vaccine research. Nano Covax phase 3 with the expected number of volunteers to participate is about 13,000 people. In phase 3, the implementation is very fast, following the correct process, and at the same time meeting the needs of disease control in Vietnam. Up to now, the Military Medical Academy has mobilized a lot of doctors, technicians, students… to participate in the testing process so that it can be ready for deployment in 10 provinces/cities across the country at the same time. country. After testing phase 1 and phase 2, Nano Covax vaccine is quite safe, so the criteria for recruiting volunteers will be relaxed more than the previous 2 phases. Volunteers participating in phase 3 from 18-75 years old, only need to check the blood count and check for antibodies to the SARS-CoV-2 virus. People who have been exposed to the SARS-CoV-2 virus or already have antibodies will be excluded from the test population. More about the phase 3 trial, Lieutenant General, Professor-Dr. Do Quyet, Director of the Military Medical Academy, Ministry of National Defense said that he believes in the safety of the Nano Covax vaccine with the results achieved. through the previous two phases of testing. According to the Director of the Military Medical Academy, immunogenicity is reflected in two main factors: antibody concentration and antibody immunogenicity. Specifically, the concentration of SARS-CoV-2 virus antibodies after injection of the phase 2 trial showed a very high increase in antibody titres, from tens to hundreds of times. Antibody immunogenicity to assess the ability to neutralize SARS-CoV-2 virus living at the 35th day of good response, above the prescribed threshold. As for the ability to neutralize the virus at day 42, the team has now evaluated 22/110 samples; expected to be completed in early June 2021 to report to the National Ethics Council in Biomedical Research. Phase 3 aims to evaluate the protective effect of the vaccine on the community, designed in many centers, expanding to other localities with a larger number of samples with only 1 injection. Based on the results of the evaluation, the National Ethical Council in Biomedical Research selected the experimental injection of 25mcg dose. Strictly following international guidelines, the National Ethical Council for Biomedical Research also identified a phase 3 trial in 10,000 people. Military Medical Academy complies with the approved outline and deploys to recruit volunteers.

The WHO Independent Panel of Experts recommends the use of Sinovac vaccine for people over 18 years of age. The evaluation data show that this vaccine is effective in protection in the elderly. Sinovac is the second Chinese vaccine approved by WHO for emergency use. (Photo: Reuters) WHO’s decision was made based on a review of the latest clinical data on the safety and efficacy of Sinovac’s vaccine as well as the company’s manufacturing practices. On May 5, the WHO technical advisory group met, reviewed and evaluated the Sinovac vaccine. WHO Director-General Tedros Adhanom Ghebreyesus said that Sinovac vaccine is safe and effective, emphasizing that it does not require a high level of vaccine preservation, suitable for low-income countries. “Now it’s important to get these life-saving tools quickly into the hands of those who need them.” , the head of WHO said. Sinovac is the second Chinese vaccine approved by WHO for emergency use. On May 7, the Sinopharm vaccine became the first vaccine not from a Western pharmaceutical company to be approved by the WHO. Meanwhile, China’s third vaccine, manufactured by CanSino Biologics, has also submitted clinical trial data. However, WHO has not yet scheduled an assessment. As of the end of May, Sinovac pharmaceutical company has supplied more than 600 million doses inside and outside China, of which more than 430 million doses have been used.

In the statement, the WHO’s independent expert panel recommended that Sinovac be given to adults over 18 years of age, with a second dose initiated every 2-4 weeks. There is no age limit for this vaccine, as data shows it is likely to protect older adults. This is the second Chinese vaccine approved by the WHO for emergency use – after the Sinopharm vaccine approved in early May. Covid-19 vaccine box manufactured by Sinovac pharmaceutical company. Photo: Anadolu Agency. A third Chinese vaccine, manufactured by CanSino Biologics, has submitted clinical trial data, but WHO has not scheduled a review. Sinovac said it had delivered more than 600 million doses of the vaccine at home and abroad as of the end of May, of which more than 430 million had been administered. In addition, China has deployed hundreds of millions of doses of its own vaccines – including Sinopharm and Sinovac – to many countries, especially in Latin America, Asia, and Africa. Many of these countries have difficulty finding a vaccine developed by the West.

At the same time, the grant helps to urgently invest in the production system of materials and equipment to ensure the supply of a sufficient number of necessary vaccines, supplemented with the amount of imported vaccines, towards the completion of the Covid-19 vaccination program. -19 for the people of Vietnam right this year. Test injection of Nanocovax vaccine phase 1 at the Military Medical Academy. Photo: Viet Linh. In phase 3, the Nanocovax vaccine will be tested in multi-centers at domestic facilities with about 13,000 volunteers. In the North, there are Military Medical Academy and Hung Yen, in the South, there are Pasteur Institutes in Ho Chi Minh City and Long An. Phase 3 is divided into several sub-phases, first injecting 800 registered volunteers, then continuing to recruit more. The optimal dose chosen for phase 3 is 25 mcg. Through the study, all 3 dose groups of 25 mcg, 50 mcg and 75 mcg produced equivalent immunity, due to the equal effectiveness, the Ethics Committee chose the lowest dose for production, saving raw materials. If all goes well, by the end of September, phase 3 testing will be complete. At that time, Vietnam can produce the first Covid-19 vaccine. Exchange with Zing Mr. Ho Nhan, founder and general director of Nanogen Company, did not comment or disclose more about this information. He said the company has stocked up enough materials to produce a vaccine right after the third phase of testing is completed. The company said that if it goes well, it can produce 100 million doses this year. Nanocovax vaccine is Vietnam’s first Covid-19 vaccine that is allowed to be tested in clinical trials, manufactured by Nanogen Company based on recombinant protein technology. The phase 1 clinical trial took place from December 17, 2020, to the end of April completed the phase 2 trial on 560 volunteers, expanding the audience from 18 to over 60 years old, of which one the number of people with underlying diseases such as hypertension, dyslipidemia, diabetes, grade 1 cardiovascular disease… are not too severe. Besides Nanocovax, the second domestic vaccine being tested is Covivac of IVAC Company, which has now completed phase 1 injection.

Japan plans to produce the vaccine domestically. Illustration: CNN Shionogi is currently in discussions with the Ministry of Health, Labor and Welfare about a framework that would allow the efficacy and safety of vaccines to be assessed even with small-scale trials. This manufacturer hopes to contribute to the early prevention of the Covid-19 pandemic by focusing on investment and management of resources. In addition, the company has also completed a production line capable of supplying 10 million people a year with vaccines and plans to increase capacity further. Regarding Moderna’s vaccine approval process, on May 10, the pharmaceutical company Takeda said that clinical trials have confirmed that Moderna’s vaccine has helped increase antibodies in vaccinated people. The Japanese Ministry of Health, Labor and Welfare will evaluate and make a decision on whether to give the vaccine a “green light” as early as May 20.

People were tested with Nano Covax vaccine phase 2. In phase 2, the volunteers were divided into 4 groups, including groups of injections with doses of 25mcg, 50mcg, 75mcg and placebo. All 3 doses of 25mcg, 50mcg and 75mcg injected to volunteers were immunogenic, of which the 25mcg dose level is considered to be the most effective. The research team will report the results of phase 2 to the Ministry of Health. It is expected that on April 27, it will submit to the National Bio-Medical Research Ethics Council of the Ministry of Health a plan to deploy the clinical trial injection of Nano Covax vaccine phase 3. According to the plan, Nano Covax vaccine in this phase will be tested in large groups, from 10,000 to 15,000 people, starting from May 5-2021. The research team is expected to propose a single test injection dose of 25 mcg. Previously, as reported by the New Hanoi News, Nano Covax was the first Covid-19 vaccine in Vietnam to be injected for clinical trials in humans, researched and developed by Nanogen Technology Joint Stock Company. In phase 2, there were 560 volunteers registered for the trial, expanding the subjects from 18 to over 60 years old, of which, some people had background diseases such as hypertension, dyslipidemia, diabetes, heart disease. 1 degree circuit … not too heavy. The test vaccination of Covid-19 Nano Covax vaccine phase 2 was held at two bridge points: the Military Medical Academy and the Pasteur Institute of Ho Chi Minh City (participating in the study, conducted in Ben Luc district, province. Long An). For objective reasons, there were 4 people who asked to withdraw from the list of experimental injections. As a result, 556 people completed the second phase of Nano Covax vaccine trial. Step 1: Access to https://www.bluezone.gov.vn or directly download at App Store or Play Store. Step 2: Once downloaded, the app will ask for Bluetooth permission to record contact with other Bluezone installed users. If Bluetooth isn’t open, drag the status notification bar and turn on Bluetooth; Or go to Settings, select Bluetooth and turn it on. Step 3: After the installation is complete, click Scan Around. If someone near you less than 2m has used Bluezone, the application will automatically identify these users and put them on the contact list.

Covid-19 vaccination for medical staff – Photo: Minh Anh The World Health Organization (WHO) has requested vigilance, monitoring, early detection and timely management of rare human events after Covid-19 vaccination with suspected immune thrombocytopenia. , scattered blood clots in the lumen, cerebral venous thrombosis. The rate of thrombosis after AstraZeneca vaccination is 4.6 / 1 million doses of the first injection, Pfizer-BioNTech Covid-19 vaccine is 0.2 / 1 million doses of the first injection. Thrombosis after AstraZeneca vaccination is mainly seen in women, in Germany there are 29 out of 31 women with thrombosis are women. The rate of blood clotting after AstraZeneca vaccination in young people is higher than in the elderly, especially in the age group 20-29. After vaccination AstraZeneca, the phenomenon of blood clotting seems less likely to occur in people over 60 years old, only about 0.2 / 1 million doses of the first injection. Complications of coagulation after AstraZeneca vaccination depend on genetic factors, underlying disease, lifestyle, medications, factor V Leiden (risk of blood clots). According to the clinical symptom guidelines, the above events are rare and usually appear 4 to 28 days after Covid-19 vaccination with persistent, severe headache; localized neurological symptoms; convulsions, blurred vision, or double vision; difficulty breathing or chest pain; stomachache; pain, swelling of the lower extremities. In particular, patients rarely present with bleeding, skin hemorrhage, or internal bleeding. The Ministry of Health believes that lower level medical facilities can completely handle the clotting phenomenon According to the Ministry of Health, at commune, ward, district or equivalent health centers of grade IV, people should be monitored after vaccination. If at least 1 of the above clinical symptoms appears, it is necessary to transfer the person after Covid-19 vaccination to a higher level or seek emergency treatment if any. In the case of the district hospital, district or equivalent grade III, after injection appears one of the above symptoms need to carry out the following tests: Count the platelet count; basic coagulation tests; quantitative D-dinmer assay; Ultrasound, X-ray exploration … In case of after injection, symptoms need to be transferred to higher level for treatment. At the provincial, city or equivalent level II health facilities, basic tests are needed to count platelet count, and basic coagulation test; quantitative D-dimer assay; imaging tests to assess thrombosis and bleeding; perform other exploration if available. In cases beyond the capacity of diagnosis and treatment, it is necessary to consult a higher level specialist. At the central grassroots level or equivalent grade I, the special class will take in people after vaccination with severe complications transferred by the levels, and carry out all necessary investigations for diagnosis and treatment according to the diagnosis and treatment guidelines of the Ministry of Health; Consult experts as needed. According to the Ministry of Health, by the morning of April 23, an additional 20,203 people were vaccinated against Covid-19 of AstraZeneca. Thus, from March 8 to now, a total of 128,610 people have been vaccinated against Covid-19 of AstraZeneca phase 1 and phase 2 in 28 provinces and cities and have not recorded any cases of blood clots later. injection.

NDV-HXP-S is the first vaccine in clinical trials to use a new molecular design that is expected to produce more antibodies than current vaccines. With that, new vaccines could be made much easier than current vaccines. Low- and middle-income countries can either produce the NVD-HXP-S vaccine on their own or buy it back at low cost from neighboring countries. Photo: NY Times Existing vaccines from companies such as Pfizer and Johnson & Johnson must be made in specialized factories using ingredients that are difficult to buy. Meanwhile, the new vaccine can be produced from eggs. According to the NY Times, eggs are the raw material that produces billions of doses of flu vaccine each year in factories around the world. If the NDV-HXP-S vaccine is proven to be safe and effective, influenza vaccine manufacturers are capable of producing more than one billion doses of the vaccine each year. Low- and middle-income countries that are currently having trouble buying vaccines from richer countries can make NDV-HXP-S vaccines themselves or buy them at low cost from neighboring countries . “That was amazing. This is going to be the game changer, ”said Andrea Taylor, assistant director of the Center for Global Health Innovation at Duke University (USA). First, clinical trials have to determine that NDV-HXP-S is indeed effective in humans. The first phase of clinical trials will end in July, and the final phase will take a few months. However, animal trials have raised hope about the prospects of the new vaccine. The key to the Covid-19 vaccine The Covid-19 vaccine works by activating a natural immune mechanism in the human body. SARS-CoV-2 virus has a round shape and many spines surrounding the surface. These spikes are also known as ‘prickly proteins’, and they act as keys to help viruses enter cells. The vaccine will cause the body to produce resistance that helps to block these dendritic cells. However, injecting only mutant proteins into the body is not the best way to make vaccines because mutant proteins sometimes assume the wrong shape and prompt the immune system to produce the wrong antibodies. This happened long before the Covid-19 pandemic broke out. In 2015, another coronavirus appeared to cause Middle East Respiratory Syndrome (MERS). Jason McLellan, a biologist at the Geisel School of Medicine at Dartmouth College, and colleagues have begun building a MERS vaccine. Researchers want to use mutant protein surges as a target, but they have to take into account the fact that mutant protein is a shape-altering substance. When the protein is about to fuse with a cell, it changes from a tulip-like shape to a javelin-like shape. McLellan and colleagues have discovered a way to keep proteins locked in a tulip-like shape is to change 2 of the more than 1,000 building blocks in the protein into a compound called proline. The protein spike to the two new proline molecules is more likely to assume tulip shape called 2P. The researchers injected the 2P mutation into mice and found that the animal could easily fend off the MERS-CoV infection. Scientists have published research on this mutant protein boost, but received little public attention. By the end of 2019, the SARS-CoV-2 virus has appeared and spread around the world. McLellan and his colleagues got into action, designing the 2P mutant for SARS-CoV-2. Within days, Moderna used that information to make the Covid-19 vaccine. Other companies quickly followed suit, applying the 2P mutation to Covid-19 vaccine makers and starting clinical trials. All three vaccines licensed so far in the US, Johnson & Johnson, Moderna and Pfizer / BioNTech, use 2P. Other vaccine manufacturers are also using 2P in vaccine trials. Novavax has had strong results with 2P mutant hemp protein increases in clinical trials and is expected to apply to the Food and Drug Administration (FDA) for an emergency license within a few weeks. next. Eggs – the simple ingredient that makes up the vaccine The first wave of Covid-19 vaccine development required the use of specialized and expensive materials for its fabrication. Moderna’s RNA-based vaccines, for example, require genetic building blocks called nucleotides as well as fatty acids. These ingredients make up a vaccine produced in purpose-specific construction factories. Meanwhile, the production of the flu vaccine is based on just one study. Many countries have huge factories to produce low-cost flu vaccines, made up of eggs. The team at the PATH Center for Vaccine Innovation and Access wondered if scientists could create a cheap Covid-19 vaccine grown in chicken eggs. In this way, a vaccine factory for the flu can also produce Covid-19 vaccine. In New York (USA), a team of scientists at the Icahn School of Medicine in Mount Sinai already knew how to create such a vaccine using a bird virus called the harmless Newcastle virus. people. For years, scientists have been studying the Newcastle disease virus to create vaccines for a wide range of diseases. To develop the Ebola vaccine, for example, researchers added an Ebola gene to the unique Newcastle virus genome. Then, the scientists put the genetically modified virus into eggs, because this is a virus that causes disease in poultry, it multiplies rapidly in the eggs. Researchers have found that the Newcastle virus is prevented by Ebola proteins. Researchers at Mount Sinai have found that the NDV-HXP-S vaccine can protect mice well from disease. “I can say, this vaccine can protect all mice against the virus SARS-CoV-2. However, many people still do not understand the effects of this vaccine on humans, “said Peter Palese, lead researcher said. According to the NY Times, one egg can make 5-10 doses of the NDV-HXP-S vaccine, compared with just 1-2 doses of the flu vaccine. “We are very excited about this, because this could be a way of making a vaccine at low cost,” said Peter Palese. For some countries, the prospect of self-production of Covid-19 vaccine is highly desirable. However, Madhavi Sunder, an intellectual property expert at the Georgetown Law School, warns that the NDV-HXP-S vaccine will not help countries like Brazil get out of pandemic immediately when they are facing the tide. New Covid-19 translation wave. “We’re not talking about billions of doses of vaccine production. Instead, this strategy will be important for long-term vaccine production, not only for the Covid-19 epidemic but also for other possible pandemics in the future, ”Madhavi Sunder said.

Ceremony of announcing and launching the Swedish Nutifood Research Institute of Nutrition

Nutifood Swedish Research Institute – NNRIS is a gathering place for a team of leading nutrition experts, doctors in the world and leading experts in Vietnam. The Institute will research and develop European standard nutritional solutions to meet the specific needs and conditions of Vietnamese children and consumers.

The first achievement of Nutifood Swedish Nutrition Research Institute – NNRIS is the FDI formula, helping children build a strong resistance – Good digestion foundation; is being clinically tested by the National Institute of Nutrition. In addition, the Institute has built a set of high-tech agricultural standards according to Swedish standards, helping Nutifood to have the first international high-standard fresh milk source in Vietnam – with a content of 3.5 grams of protein, 4.0 gram fat / 100 ml, equivalent to imported fresh milk.

Mr. Do Xuan Tuyen – Deputy Minister of Health – congratulated Nutifood’s contribution

At the ceremony, Nutifood also signed a strategic cooperation agreement with the Ministry of Health in the “Communication program to raise awareness about nutrition to prevent overweight and obesity among children in Vietnam” with the theme “For a reason. BMI “high-rise children system.

Since then, continue to carry out research activities, addressing the nutritional status for all ages such as: Nutrition for the first 1,000 days of life, Prevention of stunting in children, School nutrition, Nutrition nutrition and health care for the elderly, Clinical nutrition – gastrointestinal nutrition …

Mr. Tran Thanh Hai – Chairman of the Board of Directors of Nutifood Group gave the opening speech and was honored to announce the launch of Nutifood Nutrition Research Institute, Sweden NNRIS

At the same time, Nutifood also signed a strategic cooperation agreement with the Ministry of Health, 7 Medical Associations and 5 Universities of Medicine with the goal of bringing high-standard European nutritional solutions, suitable to the condition and nutritional needs. and nutrition of Vietnamese children and consumers, optimally contributing to the development of Vietnamese stature and intellectual potential.

Website: https://nutifood.com.vn/

Fanpage: https://www.facebook.com/nutifoodvietnam

Patient Pham Thi H. has lingering complaints about doctors from Hue Central Hospital (facility 2) not having a practice certificate, belittling the patient’s life and causing serious consequences for the patient. harm to health and spirit.

In the press release, Hue Central Hospital Unit 2 appreciates the cooperation in resolving the matter in terms of professional identification in diagnosis and treatment at Ms. Pham Thi H.’s unit.

“Through a direct meeting between the hospital and Ms. Pham Thi H. on defining professional responsibilities in diagnosis and treatment of the disease; based on the content of the professional council on April 7, 2021 with the participation of highly specialized doctors and doctors of the hospital and lawyer Nguyen Van Ky (Director of Ky Nguyen Law Firm and Associates), they I would like to synthesize and analyze the remaining problems between the parties “, the press release of Hue Central Hospital Unit 2 stated.

During and after a prolonged treatment course, patient Pham Thi H. had persistent complaints.

According to the hospital, patient Pham Thi H. was diagnosed with a large lip tumor from the hospital. Through clinical examination, subclinical, medical consultation on September 16, 2020, patient H. had surgery to remove the tumor.

After the surgery, due to the incision in a sensitive area of ​​the woman, the nurse Van is the one who directly changes the bandage every day, reports the incision and the doctor Nguyen Du Quyen asks about the wound status of the patient Pham Thi H through nursing Van.

The fact that Dr. Quyen does not directly examine patients after surgery is wrong with professional regulations and inexperience in handling sensitive medical examination and treatment issues. Currently, after the patient has had a second operation to treat wound infections, Mrs. H.’s health has been stable and progressing well.

Doctor Nguyen Du Quyen is a doctor with full clinical practice time of 18 months. The time of surgery for patient Pham Thi H. Doctor Quyen is in the process of waiting for approval for the application for a practicing certificate. Furthermore, this doctor has a certificate of Oncology Specialist Direction and a Clinical Oncology certificate.

Hue Central Hospital Unit 2 affirmed that Doctor Quyen is eligible to operate surgery for patient Pham Thi H. under the guidance and supervision of a practical instructor.

However, the Professional Council concludes that in the process of medical examination and treatment for patient H., doctor Nguyen Du Quyen has not fully implemented the contents of the professional and technical process; do not explain thoroughly and thoughtfully to patients before and after surgery; do not follow up closely patients after surgery.

Hue Central Hospital Facility 2 said, disagreeing with patient H’s claim of VND 500 million.

When the incident happened, Dr. Quyen did not report to the leadership of the department or the leader of the disease for timely handling. Along with that, the leader of the Department of Oncology – Palliative Care is not closely involved in management.

With patient complaints about the location of surgery, the hospital explained: “The patient has had two operations in the operating room, but due to the incision in the sensitive area and ensuring the patient’s sophistication, the doctor should check in the minor operating room, not perform a bed check as usual. Therefore, it is not true that patient H. reflects his surgery at the hospital warehouse ”.

The hospital repeatedly met, reorganized and introduced the discipline of reprimand and benefit deduction according to the hospital’s internal spending regulations for two related doctors, Dr. Phan Canh Duy – Dean and doctor Dr. Nguyen Du Quyen.

The proposed Hue Central Hospital 2 will be responsible for all hospital fees and surgery costs for patient Pham Thi H. and willingly to support cosmetic treatment of the surgical wound and the caregiver. multiply the amount by 50 million. However, patient H. disagrees and asks the hospital to compensate for the amount of 500 million VND. This request is not consistent with the hospital’s financial capacity and not in accordance with the law.

“In case of disapproval of the plans given by the hospital, the patient has the right to initiate a lawsuit at the People’s Court of Phong Dien district for settlement according to the provisions of Clause 2, Article 80 of the Law on Examination and Treatment 2009.“, Hue Central Hospital Facility 2 stated in the press release.